

# UC San Diego

## UC San Diego Previously Published Works

**Title**

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

**Permalink**

<https://escholarship.org/uc/item/50n6h9j1>

**Journal**

The oncologist, 25(2)

**ISSN**

1083-7159

**Authors**

Adashek, Jacob J  
Kato, Shumei  
Ferrara, Roberto  
et al.

**Publication Date**

2019-11-01

**DOI**

10.1634/theoncologist.2019-0636

Peer reviewed

# **Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?**

Jacob J. Adashek, DO<sup>1#</sup>; Shumei Kato, MD<sup>2#</sup>; Roberto Ferrara, MD<sup>3</sup>;  
Giuseppe Lo Russo, MD, PhD<sup>3</sup>; Razelle Kurzrock, MD<sup>2\*</sup>

#JJA and SK contributed equally

<sup>1</sup>Department of Internal Medicine, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA – jadashek@westernu.edu

<sup>2</sup>Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego Moores Cancer Center, La Jolla, CA, USA. – smkato@ucsd.edu; rkurzrock@ucsd.edu

<sup>3</sup>Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori, Thoracic Oncology Unit, Department of Oncology, Milan, Italy – Roberto.Ferrara@istitutotumori.mi.it; Giuseppe.LoRusso@istitutotumori.mi.it

**Keywords:** hyperprogressive disease, immunotherapy, cancer clinical trials, immune checkpoint inhibitors

**\*Corresponding Author:**

Razelle Kurzrock, MD  
Director, Center for Personalized Cancer Therapy and Clinical Trials Office  
University of California San Diego Moores Cancer Center  
3855 Health Sciences Drive  
La Jolla, CA 92093  
Office: (858) 822-3050  
Fax: (858) 246-1915  
Email: rkurzrock@ucsd.edu

**Total Words (Abstract):** 1865 (189)

**Tables:** 1

**Figures:** 0

**JJA, RF, and GRL**, have no disclosures. **SK** serves as a consultant for Foundation Medicine. **RK** has the following disclosure information: Stock and Other Equity Interests (IDbyDNA, CureMatch, Inc., and Soluventis); Consulting or Advisory Role (Gaido, LOXO, X-Biotech, Actuate Therapeutics, Roche, NeoMed, and Soluventis); Speaker's fee (Roche); Research Funding (Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine,

Guardant Health, Grifols, Konica Minolta, and OmniSeq [All institutional]); Board Member (CureMatch, Inc).

**Acknowledgements:** RK is funded in part by the Joan and Irwin Jacobs Fund and NIH P30 CA023100.

## **Abstract**

There are currently seven approved immune checkpoint inhibitors (ICI) for the treatment of various cancers. These drugs are associated with profound, durable responses in a subset of patients with advanced cancers. Unfortunately, in addition to individuals whose tumors show resistance, there is a minority subgroup treated with ICIs who demonstrate a paradoxical acceleration in the rate of growth of their tumors – hyperprogressive disease. Hyperprogressive disease is associated with significantly worse outcomes in these patients. This phenomenon, though still a matter of dispute, has been recognized by multiple groups of investigators across the globe and in diverse types of cancers. There are not yet consensus standardized criteria for defining hyperprogressive disease, but most commonly time-to-treatment failure less than two months and an increase in pace of progression of at least two-fold between pre-immunotherapy and on-treatment imaging has been used. In some patients, the change in rate of progression can be especially dramatic – up to 35- to 40-fold. *MDM2* amplification and *EGFR* mutations have been suggested as genomic correlates of increased risk of hyperprogression, but these correlates require validation. The underlying mechanism for hyperprogression is not known, but warrants urgent investigation.

## Key Points

- Hyperprogressive disease, reflecting a marked acceleration in tumor progression, after immune checkpoint blockade can occur in diverse cancer types and is associated with ~3-month overall survival
- Relative frequency of hyperprogressive disease after immune checkpoint blockade ranges from <5% to 29%
- *MDM2* amplification and *EGFR* alterations have been associated with hyperprogressive disease, but these genomic markers and their mechanism of action require validation in larger datasets.
- A change in pace of progression between pre-immunotherapy and on-treatment imaging is important to differentiate between patients who have accelerated progression on immunotherapy versus those who have an aggressive disease regardless of treatment.

Immunotherapy in the form of checkpoint blockade has resulted in impressive responses for several previously refractory tumor types. Indeed, the Food and Drug Administration (FDA) has now approved seven checkpoint inhibitors: pembrolizumab, nivolumab, durvalumab, avelumab, atezolizumab, cemiplimab, and ipilimumab.<sup>1-7</sup> Immune checkpoint inhibitors (ICIs) mediate responses by reactivating the immune system. Reactivation occurs because these antibodies interfere with checkpoints such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) that have been exploited by tumor cells to evade the immune response, a necessity if the cancer is going to survive.<sup>8</sup> The FDA approvals

notwithstanding, there are now multiple groups who have reported that a minority of patients (albeit encompassing diverse cancers), experience a dramatic acceleration in the rate of tumor progression after starting checkpoint blockade, -- a phenomenon designated hyperprogressive disease (HPD) (**Table 1**).<sup>9-20</sup> Unfortunately, in the patients who are deemed to have HPD, their median overall survival (OS) is estimated to be roughly three months.<sup>21</sup>

The phenomenon of enhanced progression after checkpoint blockade has been described with different checkpoint blockade agents and in numerous tumor types including, but not limited to, non-small cell lung, head and neck, breast, gastric, and genitourinary cancers.<sup>9-16,18-23</sup> The fact that various histologies that can be afflicted by HPD suggests that there could be common, histology-agnostic biologic/molecular mechanism(s). A final reason for the controversy around the existence of HPD may be the reluctance of physicians and other stakeholders to acknowledge that therapies like checkpoint blockade could make some patients worse. Indeed, despite HPD, our impression remains that immune checkpoint inhibitors are some of the most effective drugs ever brought into the clinical cancer arena, with transformative activity in a broad range of lethal malignancies, including long-term complete remissions in some individuals with highly refractory disease and heavy disease burden. For this reason, HPD should be considered “a toxicity,” or an immune-related adverse event (irAE) similar to other potential side effects, and should not restrict the use of these important agents. Even so, there is an urgent imperative to inform patients

of the risk of HPD, to determine the predictors of this phenomenon, and to unravel its underlying biology.

The frequency of HPD after immunotherapy varies depending on the publication, ranging from <5% to 29% (the latter reported in one study of head and neck squamous cell carcinoma).<sup>9-16,21-23</sup> One question that arises is whether or not HPD is unique to immunotherapy. One report suggests that HPD after chemotherapy can occur, albeit at a much lower rate of 5.1% (3/59) (versus ~14% after checkpoint blockade in that study).<sup>15</sup>

A key debate regarding the existence of HPD is whether or not the cancer was an aggressive one in the first place, with the thought being that rather than an induced immunologic effect, the aggressive growth is merely a lack of effective therapy (**Figure 1**). In this regard, there are varying criteria that have been proposed to define HPD (**Table 1**). For instance, Champiat and colleagues<sup>9</sup> define HPD as RECIST progression after first evaluation and  $\geq 2$ -fold increase of the tumor growth rate between the reference (prior) and the experimental periods; Kato et al<sup>10</sup> defined HPD as >50% increase in tumor burden while on checkpoint blockade compared with pre-immunotherapy, with a <2-month time-to-treatment failure (TTF) and a >2-fold increase progression pace.<sup>10</sup> Importantly, the latter requires scans approximately two months before starting immunotherapy to be compared to pre-immunotherapyscans, to exclude the possibility that the tumor had an aggressive pace of growth even before starting immunotherapy. Virtually all other research groups have almost identical definitions for HPD (**Table 1**) except for Matos Garcia et al<sup>13</sup> and Lo Russo et

al.<sup>18</sup> The first group used the following definition: TTF <2 months and increase in measurable lesions of  $\geq 10$  mm plus the following: (i) increase of  $\geq 40\%$  in target tumor burden compared to pre-immunotherapy; or (ii) increase of  $\geq 20\%$  in target tumor burden plus multiple new lesions. The second group used a similar definition, and patients with HPD had to fulfill at least three of the following clinical/radiological criteria: (i) TTF < 2 months (ii) increase  $\geq 50\%$  in the sum of target lesions major diameters between baseline and first radiologic evaluation; (iii) appearance of at least two new lesions in an organ already involved between pre-immunotherapy and first radiologic evaluation; (iv) spread of the disease to a new organ between pre-immunotherapy and first radiologic evaluation; (v) clinical deterioration with decrease in Eastern Cooperative Oncology Group (ECOG) performance status  $\geq 2$  during the first 2 months of treatment. To avoid attributing rapid progression to immunotherapy when it simply reflects aggressive disease, some have argued that criteria that identifying HPD include a comparison to a pre-baseline time period (perhaps  $\sim 2$  months) to demonstrate a substantial change in pace of tumor growth. Even this may not be valid, as patients are often on therapy during the period preceding initiation of immunotherapy. Further, this strategy could be difficult to apply when immunotherapy is administered in first line; therefore, validation of surrogate criteria that do not include a pre-baseline scan will be an important future effort.

Despite the controversy around the existence of HPD, unique response patterns after checkpoint blockade are not new.<sup>24,25</sup> For instance, a

phenomenon termed pseudoprogression has been well established after checkpoint blockade, albeit in a small subgroup of patients.<sup>25-27</sup>

Pseudoprogression is defined by the appearance of progression on scans, probably because of immune infiltration, but the patient is asymptomatic or feels better (in contrast to hyperprogression where the patient, in our experience, feels worse) (**Figure 1**). Furthermore, with pseudoprogression, scans ultimately show tumor response. Forms of pseudoprogression have also been previously described, albeit rarely, with agents outside of immunotherapy, e.g. after glioblastoma treatment and with some targeted therapeutics.<sup>28-30</sup> The relatively unique response patterns after checkpoint blockade have resulted in development of modified RECIST criteria for immunotherapy—i.e., iRECIST.<sup>31,32</sup> Importantly, with iRECIST, new lesions are assessed as per RECIST 1.1<sup>17</sup>, but are recorded separately (and not included in the sum of target lesions identified at baseline). This type of evaluation results in a new category of unconfirmed progression (iUPD). Confirmed progression (iCPD) is only assigned if, at the next imaging, an increase in the size of new lesions is seen or additional new lesions appear.

Because of the urgency associated with the rapid progression that is the hallmark of HPD, it is crucial to differentiate between hyperprogression and pseudoprogression as early as possible, even before re-imaging. With the former, checkpoint blockade should be immediately stopped; in contrast, with the latter, treatment should be continued. Liquid biopsies that interrogate serial blood-derived circulating cell-free DNA (cfDNA) may be useful in this regard. It appears, at least based on one small study, that the



genome instability number in cfDNA rises precipitously with hyperprogression, but falls with pseudoprogression, when measured at about three to six weeks after starting immunotherapy.<sup>33</sup>

Another key question in HPD is whether there are clinical or molecular features that are associated with an increased risk of accelerated growth after checkpoint blockade. Predictors of HPD have included age  $\geq 65$  years old, female gender, regional recurrence of disease, having more than two sites of metastases, low baseline highly differentiated CD4<sup>+</sup> T cells or effector memory CD8<sup>+</sup> T cells, high severely exhausted T cells or proliferating T regulatory cells, clustered CD163<sup>+</sup> PD-L1<sup>+</sup> CD33<sup>+</sup> macrophages with epithelioid morphology as well as genomic markers (mainly *MDM2/MDM4* alterations and *EGFR* alterations) (**Table 1**).<sup>9-16,18-20,22</sup>

There are inconsistencies between studies in that some have not shown age or sex to be predictors. Further, while described by several groups including ours,<sup>10,12,19,34</sup> the putative genomic correlates (e.g., *MDM2/MDM4* and *EGFR* alterations) require larger sample size validation, and an understanding of potential mechanisms by which these alterations could mediate or facilitate accelerated tumor growth after checkpoint blockade.

Despite the current uncertainty regarding molecular markers such as *MDM2* amplification and *EGFR* alterations that may predict HPD<sup>9,12,34</sup>, the use of genomic aberrations as biomarkers for immunotherapy response pattern has been previously established.<sup>35-41</sup> Indeed, although genomics and immunotherapy are often considered as separate fields, in reality, they are tightly linked.<sup>42</sup> There are various genomic aberrations that correlate with


immunotherapy response include (but are not limited to): (i) mismatch repair gene defects that result in microsatellite instability high (MSI-H); (ii) high tumor mutational burden (TMB-high); (iii) *PBRM1* and *CDK12* mutations; and (iv) *PD-L1* amplification.<sup>35-41</sup> Other biomarkers such as high PD-L1 protein expression, gut microbiome, as well as *POLE*<sup>43</sup>, *ATM*<sup>44</sup> (*TMB-mediated*), *ATR*<sup>45</sup> (*TMB-mediated*), and *CDK12*<sup>46</sup> mutations which have been shown to predict response to immunotherapy.<sup>33,47-49</sup> Of interest in this regard, pembrolizumab was granted the first tissue-agnostic approval by the FDA in patients with mismatch repair gene-altered/MSI-H solid tumors of any type, based on response rates of ~40%.<sup>1</sup> The reasons that MSI-H and TMB-high predict response to immunotherapy are probably related, since MSI-H almost inevitably leads to a high TMB.<sup>50</sup> TMB-high means that there are likely many neo-antigens produced by the tumor mutational genome and, hence, a greater chance that the reactivated immune system post-checkpoint blockade will be able to differentiate the neoplasm from normal tissue elements and target it for eradication.<sup>51,52</sup> In certain tumor types, such as clear cell renal cell carcinoma, *PBRM1* mutations have been associated with response to immunotherapy.<sup>35,40</sup> *PBRM1* encodes a subunit of the PBAF switch-sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, which regulates how tightly DNA is packaged in cells; its loss may increase expression of T cell cytotoxicity.<sup>35,40</sup> Similarly *PD-L1* amplification in Hodgkin lymphoma and various solid tumors also associates with immunotherapy benefit.<sup>39,53,54</sup> There are also several markers of tumor resistance, again of genomic origin: (i) *STK11* and *KRAS* co-mutations in lung cancer<sup>55</sup>; (ii) loss-of-function mutations in the genes encoding interferon-receptor-associated

Janus kinase 1 or Janus kinase 2, concurrent with deletion of the wild-type allele<sup>56</sup>; and (iii) truncating mutations in the gene encoding the antigen-presenting protein beta-2-microglobulin (which leads to loss of surface expression of major histocompatibility complex class I resulting in attenuated neo-antigen presentation)<sup>56</sup>. These observations suggest that genomic markers can predict response pattern after checkpoint blockade, and that their mechanism of action is not always fully understood, at least initially.

In summary, despite the numerous research teams that have documented HPD<sup>9-16,18,20-22</sup>, the existence of this phenomenon remains a matter of dispute. Indeed, an analysis of the OAK trial<sup>57</sup>, which was a randomized study of checkpoint blockade versus chemotherapy in lung cancer, did not show a difference in the number of “fast progressors” between the arms. However, this trial had no pre-immunotherapy evaluation to demonstrate whether or not the pace of progression had increased. Patients with rapid progression who do not have pre-immunotherapy imaging available may be currently difficult to designate as having HPD. Important to note however, using pre-immunotherapy imaging may not always be feasible for all treatment settings; for example, in the first-line setting not all cancer patients have available pre-immunotherapy scans. Therefore some groups (**Table 1**)<sup>13,18</sup> have suggested criteria for HPD that do not require pre-immunotherapy scans; these criteria will need to be validated in patients with existing pre-immunotherapy scans. Recent data has shown that HPD can be recapitulated in preclinical models.<sup>18</sup> As physicians make immunotherapy a mainstay of treatment in more cancer types, it will be

imperative to develop predictive markers for HPD and to understand the biology that underlies this devastating irAE.

**Figure 1. Potential outcomes after initiation of immunotherapy for the treatment of various cancers**



**Figure Legend:** Possible outcomes of treatment with immune checkpoint inhibitors over time. Durable response to treatment where target lesions shrink on imaging and remain attenuated (green), non-durable response where lesions initially response to therapy, but on subsequent surveillance imaging, lesions become resistant and increase in size (purple), disease progression where target lesions grow >20% from previous imaging (orange), pseudoproggression where tumors enlarge on imaging initially followed by decrease in size seen (blue), and hyperprogressive disease where rapid growth occurs after initiating immune checkpoint inhibitors (red).

**Table 1. Criteria for and predictors of hyperprogressive disease (HPD) according to different research groups**

Author	Criteria for HPD	Predictors of HPD
<b>Peer-Reviewed Manuscript</b>		
Champiat S et al <sup>9</sup>	RECIST progression after first evaluation and $\geq 2$ -fold increase of the TGR between pre-immunotherapy imaging and on-treatment	$\geq 65$ years old
Kato S et al <sup>10</sup>	TTF <2 months, >50% increase in tumor burden compared with baseline pre-immunotherapy imaging, and >2-fold increase in progression pace	<i>MDM2/MDM4</i> and <i>EGFR</i> alterations  Poor TTF (defined as TTF <2 months) was not associated with age, tumor type, Royal Marsden or MD Anderson score, or type of checkpoint blockade  <i>DNMT3A</i> alterations also significantly associated with poor TTF in multivariate analysis
Saada-Bouزيد E et al <sup>11</sup>	TGK <sub>R</sub> calculated as ratio of the slope of tumor growth pre-immunotherapy and the slope of tumor growth on-treatment.. HPD was defined as a TGK <sub>R</sub> $\geq 2$	HPD seen in 39% of patients with at least a locoregional recurrence and 9% of patients with exclusively distant metastases.
Ferrara R et al <sup>15</sup>	Disease progression at the first evaluation with change in TGR exceeding 50%	More than two metastatic sites prior to immunotherapy
Kanjanapan Y et al <sup>16</sup>	RECIST 1.1 <sup>17</sup> progression at the first on-treatment scan and $\geq 2$ -fold increase in TGR between pre-immunotherapy and on-treatment	Female gender-
Lo Russo G et al <sup>18</sup>	TTF <2 months, increase $\geq 50\%$ in the sum of target lesions major diameters, appearance of at least two new lesions in an organ already involved, spread of the disease to a new organ, ECOG performance status worse $\geq 2$ during the first 2 mos. HPD on the basis of 3 concomitant out of the 5 possible criteria	Clustered macrophages with epithelioid morphology and co-localization of CD163, PD-L1, and CD33 markers (defined as complete phenotype) in HPD cases
Kamada T et al <sup>19</sup>	TTF <2 months; >50% increase in tumor burden compared with pre-immunotherapy imaging, and >2-fold increase in progression speed (same as per reference 10)	PD-1 blockade facilitated the proliferation of highly suppressive PD-1 <sup>+</sup> effector (CD4 <sup>+</sup> ) T regulatory cells  1 of 3 patients with HPD had <i>MDM2</i> amplification versus 0 of 18 without HPD
Kim CG et al <sup>20</sup>	TTF <2 months or $\geq 2$ -fold increase of the TGR between pre-immunotherapy and on-treatment (same as per reference 9)	HPD was associated with lower frequency of effector/ memory (CCR7-CD45RA <sup>+</sup> ) circulating CD8 <sup>+</sup> T cells, and higher frequency of severely exhausted (TIGIT <sup>+</sup> PD1 <sup>+</sup> ) circulating CD8 <sup>+</sup> T cells
<b>Abstract Only</b>		
Singavi A et al <sup>12</sup>	Progression at first restaging on-treatment with increase in tumor size >50%, >2-fold increase in TGR	<i>MDM2/MDM4</i> , <i>EGFR</i> , amplifications on 11q13 ( <i>CCND1</i> , <i>FGF3</i> , <i>FGF4</i> , <i>FGF19</i> )

Matos Garcia I et al <sup>13</sup>	TTF <2 months and minimum increase in measurable lesions of 10mm plus: 1) increase of $\geq 40\%$ in target tumor burden compared to baseline or 2) increase $\geq 20\%$ in target tumor burden plus multiple new lesions	HPD was not associated with age, tumor type, checkpoint inhibitor regimens, previous checkpoint inhibitor or metastatic site
Kim Y et al <sup>14</sup>	Defined by TTK pre-immunotherapy versus on-treatment (details not provided)	No associations found.

**Abbreviations:** HPD = hyperprogressive disease; IO = immunotherapy; TTK<sub>(R)</sub> = tumor growth kinetic (ratio)

TGR, tumor growth rate; TTF = time to treatment failure;

## REFERENCES

1. Marcus L, Lemery SJ, Keegan P, et al: FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res, 2019
2. Nivolumab approved for lung cancer. Cancer Discov 5:OF1, 2015
3. Syed YY: Durvalumab: First Global Approval. Drugs 77:1369-1376, 2017
4. Kim ES: Avelumab: First Global Approval. Drugs 77:929-937, 2017
5. Weinstock C, Khozin S, Suzman D, et al: U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 23:4534-4539, 2017
6. Cemiplimab Approved for Treatment of CSCC. Cancer Discov 8:OF2, 2018
7. Culver ME, Gatesman ML, Mancl EE, et al: Ipilimumab: a novel treatment for metastatic melanoma. Ann Pharmacother 45:510-9, 2011
8. Ribas A, Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science 359:1350-1355, 2018
9. Champiat S, Dercle L, Ammari S, et al: Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res 23:1920-1928, 2017
10. Kato S, Goodman A, Walavalkar V, et al: Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res 23:4242-4250, 2017
11. Saada-Bouazid E, Defaucheux C, Karabajakian A, et al: Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 28:1605-1611, 2017
12. A.K. Singavi SM, D. Kilari, A. Alqwasmi, P.S. Ritch, J.P. Thomas, A.L. Martin, C. Oxencis, S. Ali, B. George.: Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) - analysis of somatic alterations (SAs). Annals of Oncology 28, 2017
13. Matos I, Martin-Liberal J, Hierro C, et al: Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials. Journal of Clinical Oncology 36:3032-3032, 2018

14. Kim Y, Kim CH, Kim HS, et al: Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC). 36:9075-9075, 2018
15. Ferrara R, Mezquita L, Texier M, et al: Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol 4:1543-1552, 2018
16. Kanjanapan Y, Day D, Wang L, et al: Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. Cancer 125:1341-1349, 2019
17. Schwartz LH, Litiere S, de Vries E, et al: RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 62:132-7, 2016
18. Lo Russo G, Moro M, Sommariva M, et al: Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res 25:989-999, 2019
19. Kamada T, Togashi Y, Tay C, et al: PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A, 2019
20. Kim CG, Kim KH, Pyo KH, et al: Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol, 2019
21. Champiat S, Ferrara R, Massard C, et al: Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 15:748-762, 2018
22. Zuazo-Ibarra M, Arasanz H, Fernandez-Hinojal G, et al: Highly differentiated CD4 T cells Unequivocally Identify Primary Resistance and Risk of Hyperprogression to PD-L1/PD-1 Immune Checkpoint Blockade in Lung Cancer. Annals of Oncology 29:viii14-viii57, 2018
23. Matos I GA, Martin-Liberal J, Hierro C, Ocho De Olza Amat M, Viapiana C, Mur G, Vieito M, Brana I, Azaro A, Perez C, Rodriguez V, Argiles G, Oliveira E, Felipe E, Muñoz-Couselo E, Tabernero J, Dienstmann R, Garralda E.: Refining criteria of Hyperprogression (HPD) with Immune Checkpoint Inhibitors (ICIs) to improve clinical applicability. Presented at the ESMO 2018 Congress, Munich, Germany, 20 October 2018
24. Popat S: Hyperprogression with immunotherapy: Is it real? Cancer, 2019
25. Borcoman E, Kanjanapan Y, Champiat S, et al: Novel patterns of response under immunotherapy. Ann Oncol 30:385-396, 2019
26. Kurra V, Sullivan RJ, Gainor JF, et al: Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes. Journal of Clinical Oncology 34:6580-6580, 2016
27. Soria F, Beleni AI, D'Andrea D, et al: Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J Urol 36:1703-1709, 2018
28. Balana C, Capellades J, Pineda E, et al: Pseudoprogression as an adverse event of glioblastoma therapy. Cancer Med 6:2858-2866, 2017
29. Benjamin RS, Choi H, Macapinlac HA, et al: We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760-4, 2007
30. Kurzrock R, Atkins J, Wheler J, et al: Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol 24:2256-61, 2013
31. Beer L, Hochmair M, Prosch H: Pitfalls in the radiological response assessment of immunotherapy. Memo 11:138-143, 2018



32. Seymour L, Bogaerts J, Perrone A, et al: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. *Lancet Oncol* 18:e143-e152, 2017
33. Jensen TJ, Goodman AM, Kato S, et al: Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. *Mol Cancer Ther* 18:448-458, 2019
34. Kato S, Ross JS, Gay L, et al: Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. *JCO Precis Oncol* 2018, 2018
35. Bratslavsky G, Gay LM, Sokol E, et al: PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment. *Journal of Clinical Oncology* 36:12091-12091, 2018
36. Goodman A, Patel SP, Kurzrock R: PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. *Nat Rev Clin Oncol* 14:203-220, 2017
37. Goodman AM, Kato S, Bazhenova L, et al: Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. *Mol Cancer Ther* 16:2598-2608, 2017
38. Chan TA, Jaffee E, Yarchoan M, et al: Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. *Annals of Oncology* 30:44-56, 2018
39. Goodman AM, Piccioni D, Kato S, et al: Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. *JAMA Oncol* 4:1237-1244, 2018
40. Miao D, Margolis CA, Gao W, et al: Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science* 359:801-806, 2018
41. Le DT, Durham JN, Smith KN, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 357:409-413, 2017
42. Subbiah V, Kurzrock R: The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. *Oncologist* 24:1-3, 2019
43. Mehnert JM, Panda A, Zhong H, et al: Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. *J Clin Invest* 126:2334-40, 2016
44. Choi M, Kipps T, Kurzrock R: ATM Mutations in Cancer: Therapeutic Implications. *Mol Cancer Ther* 15:1781-91, 2016
45. Mouw KW, Goldberg MS, Konstantinopoulos PA, et al: DNA Damage and Repair Biomarkers of Immunotherapy Response. *Cancer Discov* 7:675-693, 2017
46. Wu YM, Cieslik M, Lonigro RJ, et al: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. *Cell* 173:1770-1782 e14, 2018
47. Patel SP, Kurzrock R: PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. *Mol Cancer Ther* 14:847-56, 2015
48. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 366:2443-54, 2012
49. Sears CL, Pardoll DM: The intestinal microbiome influences checkpoint blockade. *Nat Med* 24:254-255, 2018
50. Chalmers ZR, Connelly CF, Fabrizio D, et al: Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med* 9:34, 2017
51. Yi M, Qin S, Zhao W, et al: The role of neoantigen in immune checkpoint blockade therapy. *Exp Hematol Oncol* 7:28, 2018

52. Gubin MM, Artyomov MN, Mardis ER, et al: Tumor neoantigens: building a framework for personalized cancer immunotherapy. *J Clin Invest* 125:3413-21, 2015
53. Roemer MG, Advani RH, Ligon AH, et al: PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. *J Clin Oncol* 34:2690-7, 2016
54. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med* 372:311-9, 2015
55. Skoulidis F, Goldberg ME, Greenawalt DM, et al: STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. *Cancer Discov* 8:822-835, 2018
56. Zaretsky JM, Garcia-Diaz A, Shin DS, et al: Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. *N Engl J Med* 375:819-29, 2016
57. Gandara DR, Reck M, Cardona A, et al: LBA1Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC. *Annals of Oncology* 29, 2018